Memorial Sloan Kettering Cancer Center is pleased to announce:

Practical Management Strategies and New Innovations in Prostate Radiotherapy

Thursday-Friday December 8-9, 2016

Conference Location:
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street New York, NY 10065

Featuring World Renowned Speakers Covering Cutting-Edge Topics

CALL FOR ABSTRACTS
Course Overview

The course will include coverage of the following topics:

- Comparing outcomes for surgery and radiotherapy in clinically localized disease
- Optimal management strategies to treat acute and late side effects of radiotherapy
- Tips for reducing errors and improving QA for Prostate Brachytherapy
- Updates on SBRT and Proton therapy in the treatment of Prostate Cancer
- Salvage radiotherapy after primary treatment failures and Expected Toxicity Outcomes
- Optimal Integration of Hormonal therapy with Prostate Radiotherapy
- New Developments in External Beam Treatment Planning including MR-Treatment Planning
- Guidelines for the Radiation Oncologist contouring Target and Nodal Regions
- Integrating imaging into Treatment Selection and Treatment Planning

TARGET AUDIENCE

The target audience includes Radiation Oncologists, Urologists, Medical Oncologists, Medical Physicists, Radiation Therapists, Nurses and Residents.

CALL FOR ABSTRACTS

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. The deadline for abstract submissions is 9/15/16. Visit the conference website for more information: www.mskcc.org/radiotherapy.
Course Faculty

**MSK COURSE DIRECTOR**

Michael J. Zelefsky MD  
Vice Chair, Department of Radiation Oncology; Clinical Research; Chief, Brachytherapy Service

**MSK CO-COURSE DIRECTOR**

Marisa A. Kollmeier MD  
Radiation Oncologist, Attending

Sean McBride MD MPH  
Radiation Oncologist, Attending

**MSK FACULTY**

Oguz Akin MD  
Radiologist

Stefan Both PhD  
Dept. of Medical Physics

Oren Cahlon MD  
Radiation Oncologist; Director, Proton Therapy

Gilad Cohen MS  
Senior Radiotherapy Physicist

Jonathan Coleman MD  
Urologist

James Eastham MD FACS  
Surgeon; Chief, Urology Service; Florence and Theodore Baumann/Enid Ancell Chair of Urologic Oncology

Richard M. Gewanter MD  
Radiation Oncologist; Chief, Commack/Rockville Center Radiation Oncology

Laura Happersett MS  
Radiotherapy Physicist, Sr., Dept. of Medical Physics

Margie A. Hunt MS  
Chief, Clinical Physics Service

Philip Kantoff MD  
Medical Oncologist; Chair, Department of Medicine; George J. Bosl Chair

James G. Mechalakos PhD  
Section Head of External Beam Treatment, Dept. of Medical Physics

Michael J. Morris MD  
Medical Oncologist

John P. Mulhall MD  
Director, Male Sexual and Reproductive Medicine Program

Simon N. Powell MD PhD FRCP  
Radiation Oncologist; Chair, Department of Radiation Oncology; Enid A. Haupt Chair in Radiation Oncology

Jaspreet S. Sandhu MD  
Urologic Surgeon

Susan F. Slovin MD PhD  
Medical Oncologist

Neelam Tyagi PhD  
Assistant Attending Physicist, Dept of Medical Physics

Herbert Alberto Vargas MD  
Radiologist

Wolfgang A. Weber MD  
Nuclear Medicine Physician; Chief, Molecular Imaging and Therapy Service

**INVITED FACULTY**

Kristy Brock-Leatherman PhD  
Associate Professor; Nuclear Engineering & Radiological Sciences; Associate Professor, Radiation Oncology; Associate Professor, Biomedical Engineering, University of Michigan

Juanita Crook MD  
Radiation Oncologist, BC Cancer Foundation Agency

Anthony Victor D’Amico MD PhD  
Professor, Radiation Oncology, Harvard Medical School; Chief, Genitourinary Radiation Oncology, Brigham And Women’s Hospital; Chief, Genitourinary Radiation Oncology, Dana-Farber Cancer Institute

Mark Emberton MD FRCS Urol  
Dean, Faculty of Medical Sciences, University College London

Steven Jay Frank MD  
Associate Professor, Dept of Radiation Oncology, MD Anderson Cancer Center

Carri Glide-Hurst PhD  
Senior Staff Physicist, Henry Ford Hospital

Carlo Greco MD  
Director of Clinical Research, Champalimaud Centre for the Unknown, Lisbon, Portugal

Peter Hoskin MD  
Consultant Clinical Oncologist, East and North Hertfordshire NHS Trust

Patrick McLaughlin MD  
Professor, Radiation Oncology, University of Michigan

Jeff Michalski MD MBA  
Professor, Radiation Oncology; Vice Chairman, Radiation Oncology; Chief, Genitourinary Service, Washington University in St. Louis

Allan Pollack MD PhD  
Professor and Chairman, Radiation Oncology, University of Miami

Mack Roach MD  
Professor & Chair, Department of Radiation Oncology, and Professor, Department of Urology, University of California, San Francisco

Howard Sandler MD MS  
Chair, Radiation Oncology, Cedars-Sinai Medical Center

Matthew Smith MD PhD  
Professor, Medicine, Harvard Medical School; Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital

Robert Timmerman MD  
Professor, Radiation Oncology, Neurological Surgery, University of Texas, Southwestern

Anthony Laurence Zietman MD  
Associate Director, Harvard Radiation Oncology Residency Program; Director, GU Service, Massachusetts General Hospital
SESSION A:
Comparative Outcomes and Toxicity Management
8:00-9:15 am

Comparison of Outcomes and Toxicities and QOL between Treatment Interventions
MODERATOR: Marisa A. Kollmeier MD

- Comparison of Surgery and Radiotherapy for High Risk Disease: The Urologist’s Perspective
  James Eastham MD, FACS
- Comparison of Surgery, EBRT and Brachytherapy Based Modalities for High Risk Disease - The Radiation Oncologist Perspective
  Mack Roach MD
- Comparison of Toxicity and QOL Outcomes between Surgery and Radiotherapeutic Interventions
  Jeff Michalski MD, MBA
- Panel Discussion - Q&A

9:15-10:30 am
Optimal Use of Androgen Deprivation Therapy (ADT) and Radiotherapy
MODERATOR: Sean McBride MD, MPH

- Optimal Duration of ADT for Intermediate and High Risk Disease
  Anthony Victor D’Amico MD, PhD
- Managing the Side Effects of Prolonged ADT?
  Susan Slovin MD PhD
- Maintaining Bone Health for the Patient Treated with ADT
  Matthew Smith MD, PhD
- Panel Discussion and Q&A

11:00-12:00 pm
Optimizing Management of Side Effects after EBRT and Brachytherapy
MODERATOR: Michael J. Zelefsky MD

- Addressing GI Toxicity
  Marisa A. Kollmeier MD
- Addressing GU Toxicity
  Jaspreet S. Sandhu MD
- Addressing Sexual Dysfunction
  John Mulhall MD
- Panel Discussion and Q&A

SESSION B:
Radiotherapy Treatment Interventions: Technical Aspects
12:00-1:00 pm
Imaging for Prostate Cancer- Impact on Staging and Treatment Selection
MODERATOR: Richard M. Gewanter MD

- MP-MRI: Opportunities to Assess and Predict Treatment Response
  Herbert Alberto Vargas MD
- Molecular Imaging and Novel Tracers in Prostate Cancer
  Wolfgang A. Weber MD
- Putting It All Together: Using Imaging to Inform Treatment Options
  Steven Jay Frank MD
- Panel Discussion and Q&A

1:00-2:00 pm
LUNCH BREAK

2:00-3:15 pm
Brachytherapy: Indications, Tumor Control Outcomes and Toxicity and Advances in the OR
MODERATOR: Marisa Kollmeier MD

- LDR-Indications, Relative Contraindications, and Where Are We in 2016
  Juanita Crook MD
- HDR Indications, Relative Contraindications, and Where Are We in 2016
  Peter Hoskin MD
- Advances in the Operating Room: Real Time Treatment Assessments and Imaged Based Fusions for Dose Intensification
  Michael J. Zelefsky MD
- Optimal QA in the OR- Reducing Errors
  Gilad Cohen MS
- Panel Discussion and Q&A
3:15-4:15 pm  Structure Contouring: Basic Anatomy and What’s New?
MODERATOR: Sean McBride MD, MPH
- MRI Anatomy of the Prostate and Critical Normal Tissues
  Patrick McLaughlin MD
- Contouring the Pelvic Nodes with Confidence
  Oguz Akin MD
- Multi-modality Image Registration and Fusion: Evaluating uncertainty and building confidence
  Kristy Brock-Leatherman PhD
- Panel Discussion and Q&A

4:15-4:30 pm  COFFEE BREAK

4:30-6:00 pm  Advances in External Beam Treatment Planning and Delivery
MODERATOR: Neelam Tyagi PhD
- Guidelines for Target and Normal Tissue Dose Constraints for EBRT and SBRT
  Laura Happersett MS
- Refining the State-of-the-Art: Simulation through Treatment Planning: What are the New Treatment Planning Programs Able to Accomplish?
  James G. Mechalakos PhD
- Advances in Multi-Modality Image-Based Planning and MR-Based Simulation
  Carri Glide-Hurst PhD
- Treatment Delivery: Novel Approaches to Motion Reduction and Image Guidance
  Margie A. Hunt MS
- Panel Discussion and Q&A

6:00-6:45 pm  Cocktail Reception & Poster Presentations

Friday, December 9, 2016

7:30-8:00 am  BREAKFAST

8:00-9:00 am  Department of Medicine Grand Rounds
Biomarkers and Genomics for Prostate Cancer
Philip Kantoff MD

SESSION C: Novel Radiotherapy Treatment Interventions: Clinical Aspects
9:15-10:30 am  SBRT Outcomes and Advances
MODERATOR: Michael J. Zelefsky MD
- Tumor Control Outcomes and Toxicity for SBRT
  Michael J. Zelefsky MD
- Moderate Hypofractionation
  Allan Pollack MD, PhD
- High Dose Fractionated SBRT
  Robert Timmerman MD
- Single Dose Radiotherapy for Localized Disease
  Carlo Greco MD
- Panel Discussion and Q&A

10:30-10:45 am  COFFEE BREAK

To register today, please visit:  www.mskcc.org/Radiotherapy
10:45-11:45 am  Proton Therapy: Is there an Established Role in the Treatment of Localized Disease?

MODERATOR: Oren Cahlon MD

- Clinical Outcomes & Toxicity and Tolerance Profiles and Comparison to Photon IMRT
  Anthony Laurence Zietman MD
- Treatment Planning Challenges
  Stefan Both PhD
- Cost Effectiveness of Protons versus Other Radiotherapeutic Interventions- Is there a Winner?
  Steven Jay Frank MD
- Panel Discussion and Q&A

11:45-1:00 pm  Improving Our Radiotherapy Outcomes for Intermediate and High Risk Prostate Cancer

MODERATOR: Anthony Laurence Zietman MD

- Important Considerations for Optimizing Outcomes for Local & Regional Therapy Using Radiotherapy in Intermediate and High Risk Disease
  Marisa A. Kollmeier MD
- Elective Lymph Node Irradiation for Prostate Cancer: When, How and Is it Worth it?
  Mack Roach MD
- Ongoing and Protocols in the Works for Prostate Cancer
  Howard Sandler MD, MS
- Strategies Incorporating Targeted Therapy and Novel Anti-androgen and Radiotherapy
  Sean McBride MD, MPH
- Panel Discussion and Q&A

1:00-1:45 pm  LUNCH BREAK

SESSION D: Salvage Therapy after Primary Treatment Failure

1:45-2:45 pm  Salvage Radiotherapy after Surgery

MODERATOR: Howard Sandler MD, MS

- Salvage versus Adjuvant Radiotherapy following Radical Prostatectomy
  Anthony Victor Damico MD, PhD
- Optimal Contouring and Treatment planning considerations in the Salvage Setting
  Allan Pollack MD PhD
- The Role of Hormonal Therapy in the Salvage Setting
  Anthony Laurence Zietman MD
- Panel Discussion and Q&A

2:45-3:45 pm  Salvage Options after RT failure

MODERATOR: Michael J. Zelefsky MD

- Outcomes with Brachytherapy as Salvage for Radio-Recurrent Disease
  Marisa A. Kollmeier MD
- Outcomes of Surgery and Other Approaches in the Salvage Setting
  Jonathan Coleman MD
- Focal Therapy Options and Outcomes
  Mark Emberton MD FRCS Urol
- Panel Discussion and Q&A

3:45 pm  ADJOURN
Registration

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EARLY Before 10/8/16</th>
<th>GENERAL After 10/8/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDs, PhDs, DOs, and Medical Physicists</td>
<td>$400</td>
<td>$500</td>
</tr>
<tr>
<td>MSK Alliance and MSK Alumni</td>
<td>$280</td>
<td>$350</td>
</tr>
<tr>
<td>Residents, Fellows, RNs, Medical Students and other Healthcare Providers</td>
<td>$150</td>
<td>$250</td>
</tr>
<tr>
<td>Industry Members*</td>
<td>$875</td>
<td>$875</td>
</tr>
</tbody>
</table>

*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.

TO REGISTER TODAY, PLEASE VISIT:
www.mskcc.org/Radiotherapy

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the Continuing Medical Education page on OneMSK.

CONTACT
Continuing Medical Education
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th Floor New York, New York 10017
cme@mskcc.org

COURSE DESIGN
This course includes hands-on review of cases which will be intermixed with short didactic lectures.

EVALUATION
A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

OUTCOMES MEASUREMENT SURVEY
Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 15.5 AMA PRA Category 1 Credit(s)™.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS
For information on hotels in the area of MSKCC with discounted rates, please visit: www.mskcc.org/accommodations.